Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 1192

Sort by

Sort Order Select

Journal Articles

Efficacy and Safety Results from ASCEMBL, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, vs Bosutinib (BOS) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with ≥2 Tyrosine Kinase Inhibitors (TKIs

Blood (2020) 136 (Supplement_2): LBA-4.

https://doi.org/10.1182/blood-2020-143816

Published: 2020

Journal Articles

A Prospective Haploidentical Peripheral Blood Stem Cell Transplant Study Using a Pre-Defined Conditioning Regimen Intensity Based on Age and the Hematopoietic Cell Transplantation Comorbidity Index- Anzhit 1: Encouraging Preliminary Survival Outcomes at One Year Follow up

John Moore, MB.BS, MD FRACP, FRCPA, John Kwan, MBBS,FRACP,FRCPA, David Gottlieb, MBBS, MD FRACP, FRCPA, Ashish Bajel, FRACP, David Ritchie, MB ChB, PhD FRACP, FRCPA, David T Yeung, BSc,PhDFRACP,FRCPA,MBBS, Matthew Greenwood, MBBS, FRACP, FRCPA, Duncan Purtill, MBBS,FRCPA,FRACP, Steven Tran, BEng MBiomedE, Donna Aarons, B.Pharm, Nada Hamad, MB.BS, FRACP, FRCPA

Blood (2020) 136 (Supplement 1): 51–52.

https://doi.org/10.1182/blood-2020-142131

Published: 2020

Journal Articles

Phase 1, First-in-Human Study of MEDI2228, a BCMA-Targeted ADC in Patients with Relapsed/Refractory Multiple Myeloma

Blood (2020) 136 (Supplement 1): 26–27.

https://doi.org/10.1182/blood-2020-136375

Published: 2020

Journal Articles

A Phase 1 First in Human (FIH) Study of AMG 701, an Anti-B-Cell Maturation Antigen (BCMA) Half-Life Extended (HLE) BiTE ® (bispecific T-cell engager) Molecule, in Relapsed/Refractory (RR) Multiple Myeloma (MM)

Blood (2020) 136 (Supplement 1): 28–29.

https://doi.org/10.1182/blood-2020-134063

Published: 2020

Journal Articles

The Use of Monocyte Subset Repartitioning By Flow Cytometry for Diagnosis of Chronic Myelomonocytic Leukemia

Aarya Murali, MBBS (Hons), Donna Cross, Peter Mollee, FRACP,MBBS,MSc,FRCPA

Blood (2020) 136 (Supplement 1): 41–42.

https://doi.org/10.1182/blood-2020-140966

Published: 2020

Journal Articles

Burden of Cardiovascular Events and Bleeding Is High in Myelodysplastic Syndromes

Rakchha Chhetri, MBBS, Oisin Friel, MBBS, Monika M Kutyna, MSc, Kathleen Pao Lynn Cheok, MBBS, Li Yan A Wee, BSc (Hons), Hossam Amin, Rebecca Thompson, B Pharm, Deepak Singhal, MBBS,MDFRACP,FRCPA, Kirsty M Sharplin, MBBS, Devendra K Hiwase, MBBS, MD FRACP, FRCPA, PhD

Blood (2020) 136 (Supplement 1): 34–35.

https://doi.org/10.1182/blood-2020-143319

Published: 2020

Journal Articles

Presence of Multiple High Risk Cytogenetic Abnormalities Is Associated with Rapid Progression and Shorter Survival in Newly Diagnosed Multiple Myeloma

Portia Smallbone, MBBS, Stephanie Clugston, MBBS (Hons), Rebecca De Kraa, BSc, Duncan Purtill, MBBS,FRCPA,FRACP, Matthew Wright, MBBS, FRCPA, FRACP, Michael F. Leahy, FRACP,FRCPath,FRCP, M Hasib Sidiqi, MBBS

Blood (2020) 136 (Supplement 1): 23.

https://doi.org/10.1182/blood-2020-141783

Published: 2020

Journal Articles

Differences in Clinical Presentation and Outcomes between Metropolitan and Rural Myeloma Patients

Stephanie Clugston, MBBS (Hons), Portia Smallbone, MBBS, Duncan Purtill, MBBS,FRCPA,FRACP, Dustin Hall, MBBS,FRCPA,FRACP, Rebecca De Kraa, BSc, Matthew Wright, MBBS, FRCPA, FRACP, Michael F. Leahy, FRACP,FRCPath,FRCP, M Hasib Sidiqi, MBBS

Blood (2020) 136 (Supplement 1): 44–45.

https://doi.org/10.1182/blood-2020-141784

Published: 2020

Journal Articles

The Asia-Pacific Myeloma and Related Diseases Registry: Preliminary Results of Real-World Treatment Patterns and Clinical Outcomes

Kim Huynh, BBiomedSc (Hons), PhD, Naomi Aoki, MSc, BSc, Kihyun Kim, MD PhD, Wee Joo Chng, MD PhD, Gin Gin Gan, MBBS, MRCP, FRCP, Chang-Ki Min, MD PhD, Je-Jung Lee, MD PhD, Yeow Tee Goh, MBBS, Cameron Wellard, Zoe McQuilten, MBBS, PhD, Elizabeth M. Moore, PhD, Erica M. Wood, MBBS, FRACP, FRCPA, Andrew Spencer, MBBS, FRACP, FRCPA, DM

Blood (2020) 136 (Supplement 1): 30–31.

https://doi.org/10.1182/blood-2020-136896

Published: 2020

Journal Articles

Bortezomib Induction and Consolidation in Patients with Multiple Myeloma Who Received Frontline Autologous Stem Cell Transplant

Sarah Ai Ting Tan, Steven Shih, MBChB, Scarlett Olasope, MBChB, Sharon R. Jackson, FRACP, FRCPA, Sarah Poplar, MBChB,FRCPath,FRPATH,PGCert,MRCP,ClinEd, Henry Chan, MBChB, FRACP, FRCPA

Blood (2020) 136 (Supplement 1): 33.

https://doi.org/10.1182/blood-2020-140077

Published: 2020

Journal Articles

Weekly Cyclophosphamide, Subcutaneous Bortezomib and Dexamethathasone (CyBorD) for Initial Treatment of Transplant Eligible Patients with Multiple Myeloma: Experience of Two Transplant Centres

Georgia J McCaughan, MBBS, Anvita Verma, MBBS, Silvia Ling, MBBS, PhD, Orly Lavee, MBBS FRACP FRCPA, John Moore, MB.BS, MD FRACP, FRCPA, Adam Bryant, MBBS (Hon) PhDFRACP FRCPA

Blood (2020) 136 (Supplement 1): 42–43.

https://doi.org/10.1182/blood-2020-139269

Published: 2020

Journal Articles

Improvement in Non-Relapse Mortality Following Allogeneic Transplantation for Chronic Lymphocytic Leukaemia in Australia and New Zealand: An Australasian Bone Marrow Transplant Recipient Registry Study

Blood (2020) 136 (Supplement 1): 25–26.

https://doi.org/10.1182/blood-2020-136574

Published: 2020

Journal Articles

A Shared Electronic Health Record in a Rural Setting Maintains Hematological Cancer Services Remotely during the COVID-19 Pandemic

Helen Cashman, MBBS, Eleni Mayson, FRACP, FRCPA, MBBS, MPhil, David Kliman, MBBS, Sue Vachalec, Jennifer Bell, BN, Sam Milliken, MBBS, FRACP, FRCPA, John Moore, MB.BS, MD FRACP, FRCPA, Orly Lavee, MBBS FRACP FRCPA, Barbara Withers, Nada Hamad, MBBS,BSc,MSc,FRACP FRCPA

Blood (2020) 136 (Supplement 1): 5.

https://doi.org/10.1182/blood-2020-142209

Published: 2020

Journal Articles

The Utility of Leucocyte Cell Population Data and Scattergram in Rapid Identification of Acute Promyelocytic Leukemia

Shruti Mishra, MBBS, MD PDF Hematology, Kishore Kumar, MDMBBS,DM, Ashutosh Panigrahi, MBBS, MD DM, Prabodh Das, MBBS, MD FRCPA, Somanath Padhi, MBBS MD, Gaurav Chhabra, MBBS, MD

Blood (2020) 136 (Supplement 1): 19–20.

https://doi.org/10.1182/blood-2020-142498

Published: 2020

Journal Articles

Totality of Scientific Evidence in the Development of ABP 798, a Biosimilar to Rituximab

Dietger Niederwieser, MD PhD, Caroline Hamm, MD, Patrick Cobb, MD, Theingi Thway, PhD, Cecily Forsyth, FRACP, FRCPA, MBBS, Alessandra Tucci, MD, Vincent Delwail, Roman Hajek, MD PhD, Vladimir Hanes, MD

Blood (2020) 136 (Supplement 1): 35–36.

https://doi.org/10.1182/blood-2020-142723

Published: 2020

Journal Articles

Two Rare Cases of Severe Autoimmune Dyserythropoiesis without Any Underlying Haematological Malignancy or Autoimmune Disease

James A Paterson, MD, Angela Hwang, MBBS, Stephen Wong, MBBS, FRCPA, William Sewell, MBBS, FRCPA, Joanne E. Joseph, MBBS, MD FRACP, FRCPA, Nada Hamad, MBBS,BSc,MSc,FRACP FRCPA

Blood (2020) 136 (Supplement 1): 2–3.

https://doi.org/10.1182/blood-2020-142281

Published: 2020

Journal Articles

Recurrent and Refractory Hemophagocytic Lymphohistiocytosis in an Elderly. Role of Immune Aberration Due to Myeloid Gene Mutation

Suthanthira kannan Ramamoorthy, MDFRCPA,FRCP, Tina Noutsos, BS,MBBS,FRACP,FRCPA, David Wei, MBBS,FRCPA, Alexandra Yasmin Laidman, MBBS, Ferenc Szabo, FRACP,FRCPA

Blood (2020) 136 (Supplement 1): 24–26.

https://doi.org/10.1182/blood-2020-133776

Published: 2020

Journal Articles

Phosphoproteomics Uncovers Synergy between DNA-PK and FLT3 Inhibitors in Acute Myeloid Leukaemia

Heather Murray, PhD, Anoop Kumar Enjeti, MBBS,FRCPA, FRACP, PhD MD MRCP, Richard Kahl, Hayley Flanagan, David Skerrett-Byrne, PhD, Juhura Al-Mazi, PhD, Nathan Smith, Charles de Bock, PhD, Martin Larsen, PhD, Nicole Verrills*, PhD, Matthew Dun*, PhD

Blood (2020) 136 (Supplement 1): 12.

https://doi.org/10.1182/blood-2020-142435

Published: 2020

Journal Articles

Epidemiology of Acute Myeloid Leukaemia in New Zealand: A National Cancer Registry Analysis

Henry Chan, MBChB, FRACP, FRCPA, Alana Cavadino, BSc, MSc, PhD, Clinton Lewis, MD

Blood (2020) 136 (Supplement 1): 36–37.

https://doi.org/10.1182/blood-2020-136524

Published: 2020

Journal Articles

Impact of Additional Cytogenetic Abnormalities and Complex Karyotype on Event-Free Survival in Acute Promyelocytic Leukemia: Analysis from a Single Academic Center Plus the APML4 Study

Zachary D. Epstein-Peterson, MD, Sridevi Rajeeve, MD, Andriy Derkach, PhD, Jae H. Park, MD, Eytan M. Stein, MD, Yanming Zhang, MD, Harry J Iland, MBBS FRACP FRCPA MHGSA, Martin S. Tallman, MD

Blood (2020) 136 (Supplement 1): 34–35.

https://doi.org/10.1182/blood-2020-136709

Published: 2020

NARROW

Efficacy and Safety Results from ASCEMBL, a Multicenter, Open-Label, Phase 3 Study of Asciminib, a First-in-Class STAMP Inhibitor, vs Bosutinib (BOS) in Patients (Pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with ≥2 Tyrosine Kinase Inhibitors (TKIs

A Prospective Haploidentical Peripheral Blood Stem Cell Transplant Study Using a Pre-Defined Conditioning Regimen Intensity Based on Age and the Hematopoietic Cell Transplantation Comorbidity Index- Anzhit 1: Encouraging Preliminary Survival Outcomes at One Year Follow up

Phase 1, First-in-Human Study of MEDI2228, a BCMA-Targeted ADC in Patients with Relapsed/Refractory Multiple Myeloma

A Phase 1 First in Human (FIH) Study of AMG 701, an Anti-B-Cell Maturation Antigen (BCMA) Half-Life Extended (HLE) BiTE ® (bispecific T-cell engager) Molecule, in Relapsed/Refractory (RR) Multiple Myeloma (MM)

The Use of Monocyte Subset Repartitioning By Flow Cytometry for Diagnosis of Chronic Myelomonocytic Leukemia

Burden of Cardiovascular Events and Bleeding Is High in Myelodysplastic Syndromes

Presence of Multiple High Risk Cytogenetic Abnormalities Is Associated with Rapid Progression and Shorter Survival in Newly Diagnosed Multiple Myeloma

Differences in Clinical Presentation and Outcomes between Metropolitan and Rural Myeloma Patients

The Asia-Pacific Myeloma and Related Diseases Registry: Preliminary Results of Real-World Treatment Patterns and Clinical Outcomes

Bortezomib Induction and Consolidation in Patients with Multiple Myeloma Who Received Frontline Autologous Stem Cell Transplant

Weekly Cyclophosphamide, Subcutaneous Bortezomib and Dexamethathasone (CyBorD) for Initial Treatment of Transplant Eligible Patients with Multiple Myeloma: Experience of Two Transplant Centres

Improvement in Non-Relapse Mortality Following Allogeneic Transplantation for Chronic Lymphocytic Leukaemia in Australia and New Zealand: An Australasian Bone Marrow Transplant Recipient Registry Study

A Shared Electronic Health Record in a Rural Setting Maintains Hematological Cancer Services Remotely during the COVID-19 Pandemic

The Utility of Leucocyte Cell Population Data and Scattergram in Rapid Identification of Acute Promyelocytic Leukemia

Totality of Scientific Evidence in the Development of ABP 798, a Biosimilar to Rituximab

Two Rare Cases of Severe Autoimmune Dyserythropoiesis without Any Underlying Haematological Malignancy or Autoimmune Disease

Recurrent and Refractory Hemophagocytic Lymphohistiocytosis in an Elderly. Role of Immune Aberration Due to Myeloid Gene Mutation

Phosphoproteomics Uncovers Synergy between DNA-PK and FLT3 Inhibitors in Acute Myeloid Leukaemia

Epidemiology of Acute Myeloid Leukaemia in New Zealand: A National Cancer Registry Analysis

Impact of Additional Cytogenetic Abnormalities and Complex Karyotype on Event-Free Survival in Acute Promyelocytic Leukemia: Analysis from a Single Academic Center Plus the APML4 Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only